Dexcom kicks off construction on first European manufacturing site, bringing 1,000-plus jobs to Ireland
Dexcom has joined the scrum of major U.S.-based medtech companies flocking to Ireland as a European home base.
Dexcom has joined the scrum of major U.S.-based medtech companies flocking to Ireland as a European home base.
Novo Holdings is fattening up as patients slim down. Boosted by the Wegovy windfall, the fund manager’s CEO Kasim Kutay expects to do “a fair amount” more deals in 2024 and to open a second office in Asia.
Ikena Oncology is going all in on its two lead assets. After missing out on $90 million from Bristol Myers Squibb, the biotech has outlined plans to lay off 35% of its workforce and shift resources from drug discovery to clinical development of its two top cancer prospects.
PMV Pharma is laying off 30% of its staff as the precision oncology biotech prioritizes pushing its lead solid tumor candidate toward a phase 2 trial in the coming months.
Surrozen’s inflammatory bowel disease treatment is hitting the curb after the biotech had difficulty nailing a safe dose in healthy volunteers.
Vaxxinity, an immunotherapeutic vaccine developer, is boldly going into partnership with the University of Central Florida to advance space medicine research.
Mirae Asset Capital Life Science has exited stealth mode with $50 million ready to go for certain U.S. biotechs.
CG Oncology is hoping to raise $209 million from its upcoming IPO, blazing a trail to the public markets that seems to be enticing more biotechs in the first month of the year.
Despite losing a couple of Big Pharma collaborators, Dewpoint Therapeutics is gearing up to finally take its lead biologic condensates into the clinic. But the biotech will need to clear out 18 unwanted roles and narrow its pipeline to make space for the right candidates.
Following a series of reports on the FDA’s alleged history of mishandling medical device recalls, which in turn sparked a request for a government probe of the regulator, the U.S. Government Accountability Office has agreed to take on the job.